01—Abstract
Summary
Summary of the 10-K filed February 25, 2026. Cited figures are marked; the original filing is the authoritative source.
Axon Enterprise, Inc. reported strong revenue growth in the fiscal year ending December 31, 2025, with net sales increasing by 33.5% to $2.8 billiona.
This growth was driven by robust performance in both the Connected Devices segment (up 29.1%) and the Software and Services segment (up 39.6%). Despite the top-line growth, the company experienced a loss from operations of $62.1 millionb in 2025, a decrease from the $58.5 million income from operations in the prior year. This shift was largely attributed to a significant increase in operating expenses, primarily due to higher headcount to support growth and increased stock-based compensation expenses.
Financially, Axon bolstered its liquidity position, ending the year with $1.2 billionc in cash and cash equivalents, a substantial increase driven by proceeds from debt and equity offerings. The company also completed several strategic acquisitions, including Prepared and Dedrone, further strengthening its product ecosystem.
However, a material weakness in internal control over financial reporting related to revenue recognition was identified, though remediation efforts are underway. Investors should note the company's ongoing investment in research and development, which represents a significant portion of operating expenses, reflecting a commitment to innovation.
02—Key points
Key Highlights
- Net sales increased by 33.5% year-over-year to $2.8 billion for the fiscal year ended December 31, 2025.
- The Connected Devices segment saw a 29.1% increase in net sales, driven by TASER, Personal Sensors, and Platform Solutions.
- The Software and Services segment experienced a significant 39.6% increase in net sales, attributed to user growth and premium feature adoption.
- The company reported a loss from operations of $62.1 million for 2025, compared to an income of $58.5 million in 2024, primarily due to increased operating expenses.
- Cash and cash equivalents increased substantially to $1.2 billion by year-end 2025, supported by debt and equity financing.
- Axon completed strategic acquisitions of Prepared and Dedrone to expand its technology offerings.
- A material weakness in internal control over financial reporting related to revenue recognition was identified, with remediation efforts ongoing.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2025, Axon Enterprise, Inc. kept $0.04.
- Revenue$2.78B100.0%
- Cost of revenue−$1.12B40.3%
- Gross profit$1.66B59.7%
- Operating costs−$1.72B61.9%
- Operating income−$62.1M2.2%
- Interest, other & tax$186.7M6.7%
- Net income$124.7M4.5%
04—Financials
Financial Highlights
Figures from 10-KFY2025filed February 25, 2026Financial Statements
FY2025 against FY2024
| Line item | FY2025FY2024 | Change |
|---|---|---|
| Revenue | $2.78B$2.08B | +33.5% |
| Cost of Revenue | $1.12B$841.15M | +33.3% |
| Gross Profit | $1.66B$1.24B | +33.6% |
| R&D Expenses | $684.31M$441.59M | +55.0% |
| SG&A Expenses | $1.04B$741.25M | +39.8% |
| Operating Expenses | $1.72B$1.18B | +45.4% |
| Operating Income | -$62.08M$58.54M | −206.0% |
| Net Income | $124.66M$377.03M | −66.9% |
| EPS (Basic) | $1.60$4.98 | −67.9% |
| EPS (Diluted) | $1.51$4.80 | −68.5% |
| Shares Outstanding (Basic) | 78.08M75.75M | +3.1% |
| Shares Outstanding (Diluted) | 82.37M78.56M | +4.9% |
05—Questions
Frequently Asked Questions
What was the primary driver for the decline in operating income from 2024 to 2025?
The decline in operating income was primarily driven by a significant increase in operating expenses, particularly in headcount to support business growth and higher stock-based compensation expenses, which more than offset the strong revenue growth.
How did Axon's liquidity position change in 2025?
Axon's liquidity significantly improved, with cash and cash equivalents increasing to $1.2 billion by December 31, 2025. This was primarily due to proceeds from the issuance of Senior Notes and an at-the-market equity offering program.
What is the status of the material weakness identified in internal controls?
Axon identified a material weakness in internal control over financial reporting related to revenue recognition for customer contracts. The company has implemented a remediation plan to address this, including enhanced controls for assessing and updating revenue accounting policies. While the design and implementation of these controls are complete, the material weakness will be considered remediated once these controls have operated effectively for a sufficient period.
What is the outlook for R&D spending?
Axon continued to invest heavily in research and development, with R&D expenses increasing by 55.0% in 2025 to $684.3 million, representing 24.6% of net sales. This substantial investment underscores the company's commitment to innovation and developing new technologies.
06—Continue